Trial Profile
A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Parsaclisib (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms CITADEL-203
- Sponsors Incyte Corporation
- 20 Jul 2023 Planned End Date changed from 30 Jun 2023 to 31 Jul 2024.
- 30 Nov 2022 This trial has been completed in Denmark, according to European Clinical Trials Database record.
- 28 Oct 2022 This trial has been completed in Germany, according to European Clinical Trials Database record.